When was finerenone approved?

Finerenone (brand name Kerendia) was approved by the U.S. FDA in July 2021. It’s approved for adults with chronic kidney disease associated with type 2 diabetes to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular events, and hospitalization for heart failure.

If you want, I can look up its regulatory status in other regions (e.g., EU) as well.